BiotechTube

D961H + Omeprazole

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pharmacodynamics Study

Conditions

Pharmacodynamics Study

Trial Timeline

Jul 1, 2010 → Sep 1, 2010

NCT ID
NCT01159145

About D961H + Omeprazole

D961H + Omeprazole is a phase 1 stage product being developed by AstraZeneca for Pharmacodynamics Study. The current trial status is completed. This product is registered under clinical trial identifier NCT01159145. Target conditions include Pharmacodynamics Study.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01159145Phase 1Completed

Competing Products

6 competing products in Pharmacodynamics Study

See all competitors
ProductCompanyStageHype Score
GP40141 + NplateGEROPHARMPhase 1
25
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solutionAstraZenecaPhase 1
33
AZD9977 oral suspension + AZD9977 placebo oral suspension + Fludrocortisone, tablets + Eplerenone, tabletsAstraZenecaPhase 1
33
Dienogest (81150037) + Dienogest (81150231) + Dienogest (SH T00660A) + Dienogest (81150746)BayerPhase 1
30
5 mg ACT-281959 prodrug formulation I (Group A) + 20 mg ACT-281959 prodrug formulation I (Group B) + ACT-281959 prodrug formulation I (Groups C to G doses to be defined) + ACT-281959 prodrug formulation II (Group G dose to be defined) + ACT-246475 (Group G dose to be defined) + Placebo (Groups A to F)IdorsiaPhase 1
28
VXA-A1.1 H1 Tablet Vaccine (small) + VXA-A1.1 H1 Tablet Vaccine (large)VaxartPhase 1
25

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85